Skip to main navigation Skip to search Skip to main content

Assessment of the efficacy and safety of favipiravir in patients with SARS-CoV-2 infection in United Arab Emirates: A single-center study

  • Gulf Medical University
  • JSS Academy of Higher Education & Research
  • Lebanese International University
  • Holy Spirit University of Kaslik
  • Bellevue Medical Center
  • University Hospital-Notre Dame Des Secours
  • Applied Science Private University

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Anti-viral medications are among the treatment options for coronavirus infectious disease 2019 (COVID-19) management although they are still not FDA approved for coronavirus treatment. We conducted the study to assess the efficacy, and safety of favipiravir versus symptomatic management in patients with COVID-19. Methods: A cross-sectional study included 476 participants, divided into two groups. All patients received symptomatic management, and 300 received favipiravir 1,600 mg/day on day 1 and 600 mg/day on days 2 to 5. Results: The mean age of the patients was 44.18 ± 12.24 years (49.2% females). The most described COVID-19 symptoms was cough, followed by sore throat, headache, and fever. Each side effect of favipiravir was experienced by almost 38% of the patients. The average days for symptoms relief was 4.73 ± 2.25 days. The results of the linear regression showed that the intake of favipiravir vs symptomatic management only was significantly associated with a higher mean number of days until symptoms relief. Conclusion: The results highlight that efficacy of favipiravir is not supported yet for the treatment of COVID-19 as it was associated with higher mean number of days until symptoms relief. However, no remarkable issues with safety associated with Favipiravir were observed.

Original languageEnglish
Article number2917
JournalPharmacy Practice
Volume22
Issue number2
DOIs
StatePublished - 1 Apr 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • COVID-19
  • efficacy
  • favipiravir
  • safety
  • symptomatic management

Fingerprint

Dive into the research topics of 'Assessment of the efficacy and safety of favipiravir in patients with SARS-CoV-2 infection in United Arab Emirates: A single-center study'. Together they form a unique fingerprint.

Cite this